WHILE READING about the various new technologies being introduced into the field of pediatrics, I often find myself thinking, "If only the health problems of adolescents were amenable to such advances." At last, that is about to change. The US Food and Drug Administration has approved the first commercial DNA amplification tests for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections and more approvals will follow soon. Work on a polymerase chain reaction test for the detection of Trichomonas vaginalis is also well advanced. I do not think it hyperbole to say that the availability of these new tests will revolutionize our approach to the detection of sexually transmitted diseases (STDs), a major cause of morbidity among adolescents, especially young women. The widespread availability of such tests could not come at a more auspicious time. Adolescents continue to have very high rates of STDs and current research indicates that STDs increase an individual's susceptibility to human immunodeficiency virus infection.1 Conversely, prospective studies have shown that screening for C trachomatis reduces the risk for developing pelvic inflammatory disease2 and that treatment of STDs can reduce incident cases of human immunodeficiency virus infection.3 Thus, control of STDs has never been more urgent.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Pediatrics editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
Testing for STIs
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.